Announcements Trials
Browse Landscape

Phase

Phase 1/2 5Phase 2 4Phase 1 4Phase 3 2Phase 2/3 1

Status

Completed 10Active not recruiting 5Recruiting 4Unknown 2Terminated 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2

Interventions

Cisplatin 62Carboplatin 52Paclitaxel 49Radiotherapy 47Docetaxel 42Gemcitabine 38Cyclophosphamide 36Rituximab 33Capecitabine 28Fluorouracil 27Dexamethasone 27Doxorubicin 26Prednisone 21Bevacizumab 20Pemetrexed 19Oxaliplatin 18Leucovorin 18pembrolizumab 17Vincristine 17Etoposide 17Cytarabine 15Imatinib Mesylate 14Drug Therapy 14Irinotecan 13Filgrastim 13Zoledronic Acid 12Trastuzumab 12Radiosurgery 12Erlotinib Hydrochloride 12Goserelin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Terminated × Ado-Trastuzumab Emtansine × Clear all
NCT04740918 2025-08-08

KATE3

Hoffmann-La Roche

Phase 3 Terminated
96 enrolled 16 charts
Breast

Breast Neoplasms

NCT02144012 2017-03-07

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer

Hoffmann-La Roche

Phase 3 Terminated
49 enrolled 16 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡